Presentation is loading. Please wait.

Presentation is loading. Please wait.

Ebola virus disease (EVD) جمع آوری توسط : دکتر احمد رضا مبیّن متخصص بیماریهای عفونی اسفند ماه 1393.

Similar presentations


Presentation on theme: "Ebola virus disease (EVD) جمع آوری توسط : دکتر احمد رضا مبیّن متخصص بیماریهای عفونی اسفند ماه 1393."— Presentation transcript:

1 Ebola virus disease (EVD) جمع آوری توسط : دکتر احمد رضا مبیّن متخصص بیماریهای عفونی اسفند ماه 1393

2 Ebola was first discovered in 1976 near the Ebola River in what is now the Democratic Republic of the Congo. Since then, outbreaks of Ebola among humans have appeared sporadically in Africa

3 Number of new cases of Ebola virus disease reported — Guinea, Liberia, and Sierra Leone, November 9–30, 2014

4 Definition ▫Ebola hemorrhagic fever are severe and often fatal diseases characterized by:  High fever,  headache,  malaise,  myalgia,  coagulation disorders,  multiorgan failure  sore throat,  Vomiting  in particular, the appearance of a maculopapular rash  Stomach pain  Lack of appetite

5 As the virus spreads through the body, it damages the immune system and organs. Ultimately, it causes levels of blood-clotting cells to drop. This leads to severe, uncontrollable bleeding

6

7

8 As the disease gets worse, it causes bleeding inside the body, as well as from the eyes, ears, and nose. Some people will vomit or cough up blood, have bloody diarrhea, and get a rash

9 Signs and Symptoms Fever (greater than 38.6°C or 101.5°F) Severe headache Muscle pain Weakness Diarrhea Vomiting Abdominal (stomach) pain Unexplained hemorrhage (bleeding or bruising) Symptoms may appear anywhere from 2 to 21 days after exposure to Ebola, but the average is 8 to 10 days. Recovery from Ebola depends on the patient’s immune response. People who recover from Ebola infection develop antibodies that last for at least 10 years.

10

11

12 Epidemiology Human outbreaks occur sporadically in regions of Central Africa. Recent evidence suggests that bats may play a role as a reservoir host. The manner in which filovirus outbreaks are initiated is unknown; however, it is thought that the initial cases occur as a result of contact with an infected animal. Nosocomial transmission has occurred frequently during outbreaks of filovirus hemorrhagic fever in endemic areas.

13

14 Distribution of cases of EVD, by week of reporting: Guinea, Sierra Leone, Liberia, Nigeria, Senegal and Mali, weeks 48/2013 to 5/2015, as of 27 January 2015

15

16 Districts Affected by Ebola Virus Disease in Three Countries in Africa Guinea, Liberia, and Sierra Leone

17 Medical evacuations and repatriations from EVD-affected and previously affected countries, as of 28 January 2015

18 Transmission When an infection does occur in humans, the virus can be spread in several ways to others. Ebola is spread through direct contact (through broken skin or mucous membranes) with ▫blood or body fluids (including but not limited to urine, saliva, feces, vomit, and semen) of a person who is sick with Ebola ▫objects (like needles and syringes) that have been contaminated with the virus ▫infected animals ▫Ebola is not spread through the air or by water, or in general, food. However, in Africa, Ebola may be spread as a result of handling bush meat (wild animals hunted for food) and contact with infected bats.

19

20 Notice During outbreaks of Ebola, the disease can spread quickly within healthcare settings (such as a clinic or hospital). Exposure to Ebola can occur in healthcare settings where hospital staff are not wearing appropriate protective equipment, including masks, gowns, and gloves and eye protection If instruments are not disposable, they must be sterilized before being used again

21 Risk of Exposure All cases of human illness or death from Ebola have occurred in Africa (with the exception of several laboratory contamination cases) Healthcare providers caring for Ebola patients and the family and friends in close contact with Ebola patients are at the highest risk of getting sick People also can become sick with Ebola after coming in contact with infected wildlife

22 Outbreaks Past Ebola outbreaks have occurred in the following countries: ▫Democratic Republic of the Congo (DRC) ▫Gabon ▫South Sudan ▫Ivory Coast ▫Uganda ▫Republic of the Congo (ROC) ▫South Africa (imported) Current Ebola Outbreak in West Africa The 2014 Ebola outbreak is the largest Ebola outbreak in history and the first in West Africa. The current outbreak is affecting multiple countries in West Africa

23

24 Laboratory tests used in diagnosis Timeline of InfectionDiagnostic tests available Within a few days after symptoms begin  Antigen-capture enzyme-linked immunosorbent assay (ELISA) testing  IgM ELISA  Polymerase chain reaction (PCR)  Virus isolation Later in disease course or after recovery  IgM and IgG antibodies Retrospectively in deceased patients  Immunohistochemistry testing  PCR  Virus isolation

25

26 Treatment No specific vaccine or medicine (e.g., antiviral drug) has been proven to be effective against Ebola. Symptoms of Ebola are treated as they appear. The following basic interventions, when used early, can significantly improve the chances of survival: ▫Providing intravenous fluids (IV) and balancing electrolytes (body salts) ▫Maintaining oxygen status and blood pressure ▫Treating other infections if they occur 1.Some experimental treatments developed for Ebola have been tested and proven effective in animals but have not yet been tested in randomized trials in humans. 2.Recovery from Ebola depends on the patient’s immune response. People who recover from Ebola infection develop antibodies that last for at least 10 years, possibly longer 3.kills up to 50-90% of people who are infected

27 Ebola antiviral development A number of candidate antiviral treatments have shown promise in non-human primate models. Several potential drugs have been used in experimental treatments of individual EVD cases, e.g. ▫brincidofovir (Chimerix, USA), ▫favipiravir (Toyama Chemicals, Japan and MediVector Inc., USA), ▫TKM-Ebola (Tekmira pharmaceutical Corporation, Canada) ▫ZMapp (Mapp Biopharmaceutical Inc., USA)

28 Ebola vaccines development Three vaccine candidates in advanced stages of development are being studied in clinical trials focusing on healthy adults:

29 Prevention There are no approved vaccines against Ebola viruses. Barrier nursing procedures include wearing protective clothing, masks, and eye shields. Isolation of infected patients and close contacts is essential. Avoid contact with bush meat and sick animals, particularly nonhuman primates, in endemic regions.

30

31

32 Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever, is a severe, often fatal illness in humans. The virus is transmitted to people from wild animals and spreads in the human population through human-to- human transmission. The average EVD case fatality rate is around 50%. Case fatality rates have varied from 25% to 90% in past outbreaks. The first EVD outbreaks occurred in remote villages in Central Africa, near tropical rainforests, but the most recent outbreak in west Africa has involved major urban as well as rural areas.

33 Community engagement is key to successfully controlling outbreaks. Good outbreak control relies on applying a package of interventions, namely:  case management,  surveillance and contact tracing,  a good laboratory service,  safe burials  social mobilisation.

34 Three core interventions have stopped every previous Ebola outbreak and can stop this one as well: ▫exhaustive case and contact finding, ▫effective response to patients and the community, ▫preventive interventions. Nejm.org september 25, 2014 Thomas R. Frieden, M.D., M.P.H

35

36

37

38

39

40

41 Local time on August 2, two American patients return home the day

42

43 با سپاس از توجه حاضرین دکتر احمد رضا مبیّن اسفند 93


Download ppt "Ebola virus disease (EVD) جمع آوری توسط : دکتر احمد رضا مبیّن متخصص بیماریهای عفونی اسفند ماه 1393."

Similar presentations


Ads by Google